## PHARMACOPOEIAL DISCUSSION GROUP

CODE: Q-003/04
NAME: Uniformity of Dosage Units
Revision 1

## **Harmonized provisions:**

<u>Provision</u>	<u>EP</u>	<u>JP</u>	USP
Introduction	+	+	+*
Content Uniformity	+	+	+
Mass Variation	+	+	+
Criteria	+	+	+

<sup>\*</sup>The following statement is not accepted and will not be included by the United States Pharmacopeia:

"Alternatively, products listed in item (4) above that do not meet the 25 mg/25% threshold limit may be tested for uniformity of dosage units by *Mass Variation* instead of the *Content Uniformity* test if the concentration relative standard deviation (RSD) of the drug substance in the final dosage units is not more than 2%, based on process validation data and development data, and if there has been regulatory approval of such a change. The concentration RSD is the RSD of the concentration per dosage unit (w/w or w/v), where concentration per dosage unit equals the assay result per dosage unit divided by the individual dosage unit weight. See the RSD formula in Table 2."

Mon	-harm	ONIZO	$^{A}$	+trih	utae

N/A

EP

Signature

## **Local Attributes:**

N/A	N/A	N/A
European Pharmacopoeia		
Ceste	LETEL	9(14(16
Signature	Name	Date
Japanese Pharmacopoeia		
Jor Masatosh: Narita	Toru KAWANISI Name	4/ Nov. 9 2010  Date
United States Pharmacopeia	a	

Susans. deMas

Name

JP

USP

9 November 2010

Date